Automate Your Wheel Strategy on ABT
With Tiblio's Option Bot, you can configure your own wheel strategy including ABT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABT
- Rev/Share 24.2351
- Book/Share 28.0812
- PB 4.7554
- Debt/Equity 0.2713
- CurrentRatio 1.7805
- ROIC 0.1913
- MktCap 231137744000.0
- FreeCF/Share 3.8101
- PFCF 34.721
- PE 17.1914
- Debt/Assets 0.1626
- DivYield 0.0172
- ROE 0.3076
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ABT | Oppenheimer | -- | Outperform | -- | $130 | Oct. 8, 2024 |
| Initiation | ABT | Piper Sandler | -- | Overweight | -- | $131 | Sept. 19, 2024 |
News
Abbott Benefits From Libre & Biosimilars Amid FX, Cost Headwinds
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
ABT sees a 21.6% jump in CGM sales and growing global diagnostics demand, while FX and macro pressure temper its outlook.
Read More
Abbott (ABT) Rises Higher Than Market: Key Facts
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
Abbott (ABT) closed the most recent trading day at $132.85, moving +0.63% from the previous trading session.
Read More
Abbott Stock Gains Following FDA Approval of the Tendyne System
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
ABT wins FDA approval for its Tendyne TMVR system, offering a minimally invasive mitral valve replacement for high-risk patients with severe MAC.
Read More
4 Dividend Aristocrats Are Absolutely Crushing the S&P 500 in 2025
Published: May 23, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors love dividend stocks because they provide dependable passive income streams and an excellent opportunity for solid total return.
Read More
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Stifel Has Big Second-Half Stock Market Concerns: 5 Defensive Value Dividend Stocks Buys
Published: May 20, 2025 by: 24/7 Wall Street
Sentiment: Neutral
If there is one voice on Wall Street that we always listen to, it is Stifel's Barry Bannister, and with good reason.
Read More
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
Abbott Reveals Positive Outcome From REFLECT Studies, Stock Climbs
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Per REFLECT studies, ABT's Libre technology is the first CGM linked to fewer hospitalizations for heart complications in people with diabetes.
Read More
Abbott (ABT) Up 1.8% Since Last Earnings Report: Can It Continue?
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) reported earnings 30 days ago. What's next for the stock?
Read More
Abbott's Libre® Technology is First Continuous Glucose Monitor Associated with Reduced Hospitalizations for Heart Complications in People with Diabetes
Published: May 15, 2025 by: PRNewsWire
Sentiment: Neutral
New data reveal a 78% reduction in cardiovascular disease-related hospitalizations for people living with Type 1 diabetes with prior severe low blood sugar episodes.1 This significant decrease is linked to the use of Libre biowearable technology compared to traditional blood glucose monitors.1 Results also show a reduction in hospitalization for cardiovascular complications in adults with Type 2 diabetes on insulin using Libre technology.2 ABBOTT PARK, Ill., May 15, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from its REFLECT real-world studies that show the use of FreeStyle Libre® continuous glucose monitoring (CGM) technology is associated with a significant reduction …
Read More
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at Races
Published: May 01, 2025 by: PRNewsWire
Sentiment: Neutral
The test, run on Abbott's portable i-STAT ® Alinity® hand-held instrument, uses whole blood to help evaluate patients 18 years of age and older with a suspected mild traumatic brain injury, or concussion, producing lab-quality results in 15 minutes The test will be used by healthcare professionals in the medical facilities at all MotoAmerica races in 2025 ABBOTT PARK, Ill., and IRVINE, Calif.
Read More
PBH or ABT: Which Is the Better Value Stock Right Now?
Published: April 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
3 Dividend Stocks to Buy and Hold for the Next Decade
Published: April 28, 2025 by: The Motley Fool
Sentiment: Positive
Many income investors would love to have a low-maintenance portfolio that doesn't require constant attention. They'd prefer to buy great stocks and rake in the dividends without any hiccups.
Read More
Abbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction System Pacing Technology
Published: April 27, 2025 by: PRNewsWire
Sentiment: Neutral
Late-breaking data from Abbott's groundbreaking first-in-human study demonstrated successful implantation of the company's AVEIR Conduction System Pacing (CSP) leadless pacemaker Enrollment has also begun in the ASCEND CSP pivotal clinical trial to evaluate Abbott's investigational CSP Implantable Cardioverter-Defibrillator (ICD) lead Conduction System Pacing is an evolving technique specifically designed to deliver pacing to the left bundle branch area of the heart to restore its natural electrical rhythm SAN DIEGO , April 27, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data from the AVEIR™ Conduction System Pacing (CSP) acute clinical feasibility study, which demonstrated the safety and performance of …
Read More
EPD Growth in Emerging Market Supports Abbott Stock Amid Macro Woes
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Read More
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Published: April 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
2025 Dividend Kings: Weathering Tariff Volatility Better Than The Market
Published: April 23, 2025 by: Seeking Alpha
Sentiment: Positive
The Dividend Kings are outperforming the S&P 500 in 2025 by 8.94%. Top performers include National Fuel & Gas (+28.88%), Consolidated Edison (+28.10%), and Middlesex Water Company (+21.00%). Promising Dividend Kings identified in March showed relative outperformance, averaging -3.15% vs. -8.16% for SPY.
Read More
Abbott Laboratories shares gain on first quarter earnings beat
Published: April 16, 2025 by: Proactive Investors
Sentiment: Positive
Abbott Laboratories (NYSE:ABT) reported a profit beat for the first quarter driven by growth in its medical devices and diabetes care segments, as revenue fell short of estimates. The healthcare company beat earnings estimates by $0.02 with earnings per share (EPS) of $1.09 as revenue of $10.36 billion missed expectations of $10.41 billion.
Read More
Abbott (ABT) Q1 Earnings Beat Estimates
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) came out with quarterly earnings of $1.09 per share, beating the Zacks Consensus Estimate of $1.07 per share. This compares to earnings of $0.98 per share a year ago.
Read More
Abbott's Q1 Earnings Coming Up, Medical Devices Arm in Focus
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
ABT's Structural Heart, Rhythm Management and Neuromodulation businesses are likely to have driven its first-quarter 2025 performance.
Read More
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Read More
5 Defensive Stocks to Buy for a Safe Portfolio Amid Tariff-Led Mayhem
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Five defensive stocks to buy at this soaring volatility are TAP, CNP, WEC, BSX, HCA.
Read More
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
Published: April 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Global Expansion in EPD and Innovations Support Abbott Stock
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
ABT Stock to Gain From Early CE Mark Approval of Volt PFA System
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott achieves early CE Mark approval for the Volt PFA system.
Read More
New Late-Breaking Data Reinforce Benefits of Abbott's TriClip™ for People With Leaky Tricuspid Heart Valve
Published: March 31, 2025 by: PRNewsWire
Sentiment: Neutral
TRILUMINATE™ Pivotal data presented at the American College of Cardiology's Annual Scientific Session (ACC.25) and simultaneously published in Circulation show the Abbott TriClip system reduces heart failure hospitalizations The latest results highlight significant improvements in tricuspid regurgitation and quality of life through two years ABBOTT PARK, Ill., March 31, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data from its TRILUMINATE™ Pivotal trial that show the TriClip™ transcatheter edge-to-edge repair (TEER) system to treat tricuspid regurgitation (TR), or a leaky heart valve, offers substantial and sustained improvements in the severity of TR after two years.
Read More
Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms
Published: March 27, 2025 by: PRNewsWire
Sentiment: Neutral
Abbott's Volt™ PFA System is designed to provide a new therapy option for people battling heart rhythm disorders such as atrial fibrillation Pulsed field ablation – or PFA – uses high energy electrical pulses for ablation procedures that may offer benefits to targeting and treating tissue in the heart Abbott's Volt PFA System is designed to overcome limitations of existing PFA systems, providing improved workflows and a clearer indication of contact between the Volt PFA catheter and targeted tissue ABBOTT PARK, Ill., March 27, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received CE Mark in Europe for …
Read More
Abbott Hosts Conference Call for First-Quarter Earnings
Published: March 26, 2025 by: PRNewsWire
Sentiment: Neutral
ABBOTT PARK, Ill., March 26, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2025 financial results on Wednesday, April 16, before the market opens.
Read More
About Abbott Laboratories (ABT)
- IPO Date 1980-03-17
- Website https://www.abbott.com
- Industry Medical - Devices
- CEO Mr. Robert B. Ford
- Employees 114000